NCT03094507View on ClinicalTrials.gov

The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

April 19, 2017

Primary Completion Date

January 17, 2018

Study Completion Date

March 17, 2018

Conditions

HIV

Interventions

DRUG

Tivicay

50 mg once daily

DRUG

Rezolsta

darunavir 800 mg/cobicistat 150 mg once daily

Trial Locations (1)

SW10 9NH

St Stephen's Centre, London

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

lead

St Stephens Aids Trust

OTHER

NCT03094507 - The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers | Biotech Hunter | Biotech Hunter